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  LIQUID CHROMATOGRAPHY AND 
LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY ANALYSIS OF 
DONEPEZIL DEGRADATION PRODUCTS 
Article Highlights 
• Forced degradation study was performed on Donepezil hydrochloride in solution 
• Acid and alkali hydrolysis, oxidation mediated by hydrogen peroxide and thermal 
treatment were used 
• Parent HPLC method was converted to LC-MS compatible method 
• Degradation products observed were monitored by LC-MS 
 
Abstract 
This study describes the investigation of degradation products of donepezil 
(DP) using a stability-indicating RP-HPLC method for determination of done-
pezil, which is a centrally acting reversible acetylcholinesterase inhibitor. In 
order to investigate the stability of the drug and formed degradation products, a 
forced degradation study of the drug sample and finished product under differ-
ent forced degradation conditions was conducted. Donepezil hydrochloride 
and donepezil tablets were subjected to stress degradation conditions recom-
mended by the International Conference on Harmonization (ICH). Donepezil 
hydrochloride solutions were subjected to acid and alkali hydrolysis, chemical 
oxidation and thermal degradation. Significant degradation was observed 
under alkali hydrolysis and oxidative degradation conditions. Additional deg-
radation products were observed under the conditions of oxidative degrad-
ation. The degradation products observed during forced degradation studies 
were monitored using the developed high performance liquid chromatography 
(HPLC) method. The parent method was modified in order to obtain LC-MS 
compatible method, which was used to identify the degradation products from 
forced degradation samples using high resolution mass spectrometry. The 
mass spectrum provided the precise mass from which the molecular formula of 
the drug substance and formed degradation products was derived, and proved 
the specificity of the method unambiguously. 
Keywords: donepezil hydrochloride; forced degradation; stability-indi-
cating HPLC method; liquid chromatography-mass spectrometry. 
 
 
Donepezil hydrochloride is a new anti-Alzheimer 
drug. It is a potent acetylcholine esterase inhibitor, che-
mically known as 2,3-dihydro-5,6-dimethoxy-2-[[1- 
-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one 
hydrochloride (also known as aricept). It has an empi-
rical formula of C24H29NO3HCl and molecular weight 
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of 415.96. Donepezil hydrochloride was the first 
piperidine type reversible based inhibitor of the 
enzyme acetylcholinesterase (AChE). Its main thera-
peutic use is in the treatment of Alzheimer’s disease 
where it is used to increase cortical acetylcholine. 
Donepezil is postulated to exert its therapeutic effect 
by enhancing cholinergic function. In vitro studies 
have demonstrated that donepezil hydrochloride has 
a significantly greater degree of selectivity of AChE in 
the central nervous system than for butyrylcholine-
sterase in the periphery [1-3]. The molecular structure 
of donepezil is given in Figure 1. 
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Figure 1. The structure of donepezil. 
The different analytical techniques reported so 
far for analysis of this drug in biological samples and 
in pharmaceutical formulations include electropho-
resis [4] and UV-Visible spectrophotometry [5]. Sev-
eral HPLC methods for assay and LC-MS method for 
analysis of donepezil hydrochloride have been pre-
viously published [6-9]. 
Chemical stability of pharmaceutical molecules 
is a matter of great concern as it affects the safety 
and efficacy of the drug product. Organic impurities 
can arise during the manufacturing process and sto-
rage of the drug substances and drug products under 
the influence of various environmental factors and 
criteria for their acceptance up to certain limits are 
based on the pharmaceutical studies or known safety 
data. The identification and qualification of degrad-
ation products in pharmaceuticals is important since 
impurities may cause the undesirable effects on the 
patients and on the other hand may have influence on 
quality, safety and efficacy of the drug product 
[10,11].  
Knowledge of the stability of a molecule helps in 
selecting proper formulation and packaging, as well 
as providing proper storage conditions and shelf life, 
which is essential for registration of pharmaceutical 
for human use. 
HPLC methods should be able to separate, 
detect, and quantify the drug-related degradants that 
can form on storage or during manufacture of drug 
product, plus detect and quantify any drug-related 
impurities that may be introduced during drug syn-
thesis [12]. Forced degradation is a process that 
involves degradation of drug products and drug sub-
stances under more severe conditions than those 
used in accelerated stability studies, and thus gen-
erate degradation products that can be studied to 
determine the stability of the molecule [13]. 
Many authors have reported the studies on deg-
radation of donepezil [14-22]. Pappa et al. observed 
degradation of donepezil in 1 mol/L HCl, 1 mol/L 
NaOH and 30% of H2O2 under reflux. Degradation 
products were not characterized [17]. 
Dutt et al. studied degradation of donepezil hyd-
rochloride under acid/base and oxidation conditions. 
They observed 9.3% of degradation under used base 
conditions and no significant degradation under acid 
or oxidation conditions [18]. 
Al-Zoman et al. found that around 8% of the DP 
enantiomers was degraded under acid stress for 48 h. 
Whereas, under alkaline stress conditions 14% 
degradation of DP enantiomers was observed. The 
complete degradation of the DP enantiomers under 
oxidative degradation treatment using 30% H2O2 was 
achieved and 28% when using 3% H2O2 for 48 h. It 
was found that under heat stress conditions at 60 °C 
DP enantiomers were largely unstable and degrad-
ation of 60% was observed [19]. 
Chothe et al. were investigated stability of done-
pezil hydrochloride using stability indicating high per-
formance liquid chromatography. Stability study was 
performed in 1 mol/L HCl, 2 mol/L NaOH, 6% H2O2, 
neutral, photolytic and dry heat conditions. The 
authors observed fast hydrolysis in alkaline condition 
in comparison to oxidative and neutral conditions [20]. 
Abbas et al. performed forced degradation study 
according to the ICH guidelines for acidic, alkaline 
and oxidative conditions and photo degradation. It 
was found that donepezil hydrochloride is stable 
under acidic and alkaline conditions but liable to deg-
radation with hydrogen peroxide [21]. 
In addition, the oxidative ability of donepezil 
hydrochloride, was examined at a gold electrode in 
pH 3 phosphate buffer solution using cyclic linear 
sweep voltammetry. Electrochemical degradation was 
performed for predicting its oxidative stability as well 
as for recognition of the involvement of the oxidative 
process in the formation of the hydroxyl derivative of 
donepezil. The identification and characterization of 
the major product formed during the potential cycling 
and isolated by preparative high performance liquid 
chromatography, was performed by high resolution 
mass spectrometry and 1D and 2D nuclear magnetic 
resonance spectroscopy. Hydroxy donepezil deriva-
tive formed by hydroxylation reaction is identified as 
the major electrochemical oxidation product from 
donepezil [22].  
The probable degradation products of drug sub-
stance can be produced using certain stress con-
ditions like hydrolytic (acidic, basic, etc.), oxidative, 
thermal, photolytic, etc. The ICH guideline states that 
stress testing is intended to identify the likely degrad-
ation products, which further helps in determination of 
the intrinsic stability of the molecule and establishing 
degradation pathways, and to validate the stability 
indicating procedures used [23,24].  
The aim of this work is the investigation of 
forced degradation behavior of donepezil hydrochlo-
ride under various stress conditions using reversed 
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phase liquid chromatography and liquid chromato-
graphy coupled with high resolution mass spec-
trometry technique. To our present knowledge, no 
forced degradation study is reported which includes 
analysis of degradation products of donepezil hydro-
chloride using HPLC method coupled with high resol-
ution mass spectrometry technique.  
EXPERIMENTAL  
Materials and methods 
Donepezil hydrochloride and donepezil hydro-
chloride chemical reference standard (CRS), were 
kindly provided from Hemofarm A.D. (Vršac, Serbia). 
HPLC grade of methanol and acetonitrile were pur-
chased from J.T. Baker, potassium dihydrogen ortho-
phosphate, orthophosphoric acid, ammonium acetate, 
hydrochloric acid, hydrogen peroxide were purchased 
from Merck. Sodium hydroxide was purchased from 
J.T. Baker. All chemical used were of analytical 
grade. For preparing solution of ammonium acetate 
purified water was used. 
Apparatus 
HPLC analysis were performed using a HPLC 
system consists of an Agilent 1100 series vacuum 
degasser, G1311A quaternary pump, G1329A auto 
sampler with column oven and G1316A PDA Detec-
tor. Separation was achieved on C18 250 mm×4.6 
mm, 5 μm column (Wakosil II 5C 18RS) at the flow 
rate of 1.0 mL/min. Column temperature was 25 °C. 
The mobile phase consists of A (57%) and B (43%). 
The mobile phase A was phosphate buffer (2.72 g of 
potassium dihydrogen orthophosphate with 5 mL tri-
ethylamine in 1000 mL water adjusted to pH 5.0±0.05 
using 20% aqueous orthophosphoric acid) and mobile 
phase B was pure methanol. The injection volume 
was set to 20 μL. These chromatographic conditions 
were employed for testing of donepezil HCl degrad-
ation products in bulk electrolyte at detection wave-
length 230 nm. 
LC-MS Analysis 
For LC-MS analysis of the selected degraded 
samples, the parent method was modified in order to 
have LC-MS compatible method. Potassium dihydro-
gen orthophosphate was replaced with 10 mmol 
ammonium acetate solution in the aqueous com-
ponent of the mobile phase. Aqueous phase and 
methanol proportion was kept same, i.e., 57:43 and 
apparent pH adjusted at 5.0 with glacial acetic acid. 
The mobile phase was run at a flow rate of 1.0 
mL/min on the same column. These chromatographic 
conditions eluted the drug as a sharp peak at 18 min 
and also resolved the degradation products formed 
under varied forced conditions. 
HPLC system (Agilent 1200 Series, Agilent 
Technologies) equipped with degasser, autosampler, 
Wakosil II 5C 18RS column (250 mm×4.6 mm i.d., 5 
μm particle size) and DAD detector coupled with 6210 
time-of-flight LC-MS systems (Agilent Technologies) 
was used. An isocratic MS compatible method and 
the mobile phase consisted of 2.3 g/L of ammonium 
acetate solution-methanol (57:43, V/V) was used. The 
flow rate was maintained at 1.0 mL/min. The injection 
volume was 20 μL and the column temperature was 
maintained at 25 °C. The chromatograms were moni-
tored at 230 nm. A personal computer system running 
Mass Hunter Workstation software was used for data 
acquisition and processing.  
The positively charged molecular ions were 
obtained with electrospray ionization (ESI) at atmo-
spheric pressure: the eluted compounds were mixed 
with nitrogen in the heated nebulizing interface, and 
polarity was tuned to positive with the following ESI 
parameters: capillary voltage 4.0 kV, gas temperature 
350 °C, drying gas flow rate 12 L/min, nebulizer pres-
sure 45 psig (310.26 Pa), and fragmentor voltage 70 
V. Mass spectra were acquired over an m/z range of 
100-1500. 
Procedure for forced degradation study  
Preparation of sample solution 
Thermal degradation. Investigation of the deg-
radation of donepezil hydrochloride under the inf-
luence of the heat is carried out by the following pro-
cedure: 
Accurately weighed 100 mg of donepezil hydro-
chloride (or equivalent of finely powdered donepezil 
tablets) was heated for 72 h at a temperature of 105 
°C on the heated plate. Then, accurately weighed 25 
mg of thermal treated sample of donepezil hydrochlo-
ride (or equivalent of finely powdered donepezil tab-
lets) was transferred into volumetric flask and diluted 
to 50 mL with mobile phase.  
Acid hydrolysis. Investigation of the degradation 
of donepezil hydrochloride under acidic conditions in 
solution was performed using the following procedure: 
Accurately weighed 25 mg of donepezil hydro-
chloride (or equivalent of finely powdered donepezil 
tablets) was transferred into 50 mL volumetric flask, 5 
mL of 5 mol/L HCl was added and the solution was 
heated for 60 min at 80 °C. The solution was there-
after neutralized with 5 mL of 5 mol/L NaOH. The 
solution was cooled to room temperature and diluted 
to 50 mL with mobile phase.  
A.R. MLADENOVIĆ et al.: LIQUID CHROMATOGRAPHY AND… Chem. Ind. Chem. Eng. Q. 21 (3) 447−455 (2015) 
 
450 
Alkaline hydrolysis. Investigation of the degrad-
ation of donepezil hydrochloride under alkaline con-
ditions in solution was performed using the following 
procedure: 
Accurately weighed 25 mg of donepezil hydro-
chloride (or equivalent of finely powdered donepezil 
tablets) was transferred into a 50 mL volumetric flask. 
In the first experiment, 5 mL of 0.1 mol/L NaOH was 
added and the solution was stored at room tempe-
rature for 8 h. Thereafter the solution was neutralized 
with 5 mL of 0.1 mol/L HCl. The second experiment 
was carried out using 5 mL of 5 mol/L NaOH and the 
solution was heated for 30 minu at 80 °C. The sol-
ution was thereafter neutralized with 5 mL of 5 mol/L 
HCl. For LC-MS analysis donepezil hydrochloride was 
treated with 5 mL of 5 mol/L NaOH and the solution 
was heated for 1 h at 80 °C, after which the solution 
was neutralized with 5 mL of 5 mol/L HCl. 
In third experiment donepezil hydrochloride was 
treated with 5 mL of 5 mol/L NaOH at reflux for 8 h. 
Thereafter the solution was neutralized with 5 mL of 5 
mol/L HCl. 
After neutralization, all solutions were cooled to 
room temperature and diluted to 50 mL with mobile 
phase. 
Oxidative degradation. Investigation of the oxi-
dative degradation of donepezil hydrochloride through 
the use of hydrogen peroxide in the solution is carried 
out by the following experiments: accurately weighed 
25 mg of donepezil hydrochloride (or equivalent of 
finely powdered donepezil tablets) was transferred 
into a 50 mL volumetric flask. In the first experiment, 5 
mL of 3.0% H2O2 was added, and the solution was 
heated for 30 min at 80 °C. The solution was cooled 
to room temperature and diluted to 50 mL with mobile 
phase. For LC-MS analysis, donepezil hydrochloride 
was treated with 3.0% H2O2 and the solution was 
heated for 1 h at 80 °C and then diluted to 50 mL with 
mobile phase. 
In second experiment donepezil hydrochloride 
was treated with 30% H2O2 at reflux for 8 h, after 
which the solution was diluted to 50 mL with mobile 
phase. 
All solutions were filtered through a 0.45 μm 
membrane filter RC discarding the first 2 mL of filtrate 
before injecting into HPLC system. 
RESULTS AND DISCUSSION 
Investigation of forced degradation study of 
donepezil hydrochloride and donepezil tablets was 
originally performed using parent HPLC method. 
Results from chromatographic peak purity testing 
obtained by HPLC analysis of the all forced degrad-
ation samples showed spectral homogeneity of drug 
substance peak, proving that is spectrophotometric-
ally pure and well resolved from all of its degradation 
products thus confirming the stability indicating nature 
of the method.  
Besides HPLC analysis of donepezil hydrochlo-
ride degradation products under stress conditions, 
LC-MS analysis was performed. In our preliminary 
experiment, forced degradation study was carried out 
by subjecting donepezil hydrochloride to hydrolytic 
degradation under acidic and alkali conditions, chem-
ical oxidation and thermal degradation in order to 
achieve the complete degradation of donepezil hydro-
chloride.  
Hydrolytic degradation in acid conditions in 5 
mol/L HCl at 80 °C for 1 h was performed and showed 
that donepezil hydrochloride was stable under the 
applied conditions. No significant degradation (less 
than 1% of degradation) of donepezil and donepezil 
finished product was observed when donepezil hydro-
chloride was exposed to acid hydrolysis conditions. 
When donepezil was exposed to acid, there was no 
significant change in the peak area for donepezil and 
no significant additional peaks were detected. The 
degradation of donepezil and donepezil tablets samples 
was negligible in acid hydrolysis condition and only in 
acid hydrolysis of donepezil tablets sample two deg-
radation products as minute peaks were observed. 
Significant degradation of donepezil hydrochloride 
and donepezil finished product was observed when 
exposed to alkali hydrolysis and hydrogen peroxide. 
Hydrolytic degradation in alkali conditions in 0.1 
mol/L NaOH performed at room temperature for 8 h 
showed that donepezil hydrochloride was stable 
under the applied conditions. But the degradation was 
achieved at more drastic conditions. Donepezil drug 
was found to undergo degradation under alkali con-
dition (5 mol/L NaOH). About 1 to 1.5% of donepezil 
was degraded after exposure of donepezil and done-
pezil tablets in alkali hydrolysis condition with form-
ation of a few major products. For LC-MS analysis 
donepezil hydrochloride was subjected to hydrolytic 
degradation under alkali conditions (5 mol/L NaOH) at 
80 °C for 1 h. The obtained HPLC chromatogram is 
shown in Figure 2b. It was recorded that 3% of 
donepezil hydrochloride was degraded. In order to 
obtain the maximum degree of degradation donepezil 
hydrochloride was conducted to 5 mol/L NaOH at 
reflux for 8 h. The degree of obtained degradation of 
donepezil hydrochloride was about 15%.  
Donepezil hydrochloride also undergoes deg-
radation in oxidative conditions with 3% hydrogen 
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peroxide. Donepezil was very sensitive towards oxi-
dation degradation mediated with hydrogen peroxide. 
When oxidation degradation of donepezil and done-
pezil tablets was performed in 3% hydrogen peroxide 
solution at 80 °C, about 1.5 and 3.5% of degradation 
occurred, respectively. For LC-MS analysis oxidative 
degradation with 3% H2O2 of donepezil hydrochloride 
performed at 80 °C for 1 h showed about 12% done-
pezil degradation (Figure 2c). In order to obtain maxi-
mum degree of degradation sample was conducted to 
30% H2O2 at reflux for 8 h. The degree of obtained 
degradation of donepezil hydrochloride was 57%. 
Thermal degradation of donepezil hydrochloride 
was performed at 105 °C for 72 h (Figure 2d). In 
thermal degradation samples degradation of done-
pezil was also negligible and several degradation 
products as minute peaks were detected in thermal 
treated donepezil hydrochloride and in thermally treated 
donepezil tablets. The degree of obtained deg-
radation of donepezil hydrochloride was about 1%.  
Based on the investigation of forced degradation 
behavior in our work, donepezil was found to be 
stable under mild acidic condition and alkaline con-
dition, but sensitive to degradation with hydrogen per-
 
Figure 2. Chromatograms of a, b, c and d samples obtained from untreated, alkali, peroxide and thermal stress testing of donepezil 
hydrochloride, respectively, using LC-MS compatible method. 
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oxide, which is also reported in earlier studies on 
stability of donepezil hydrochloride [17-21]. Even if it 
appears stable under mild conditions, in our experi-
ment degradation was achieved in alkaline solution 
under more severe conditions, using high molarity 
alkaline solution and reflux. Similar results were rep-
orted in earlier studies where degradation under alka-
line conditions was performed using reflux [17] or pro-
longed time of treatment with higher alkaline concen-
tration [18–20]. Also, in our study donepezil hydrochlo-
ride showed lower degree of degradation under 
applied conditions for thermal stress, but it is reported 
that under prolonged exposure to high temperature 
considerable degradation was induced [19]. 
Characterization of degradation products by LC-MS 
For LC-MS analysis of the selected degraded 
samples, the parent HPLC method was modified in 
order to have LC-MS compatible method. LC-MS 
procedure included alkaline, oxidative and thermal 
degradation of donepezil hydrochloride. The results 
are given in Figure 2 and Tables 1-3.  
Table 1 shows the results of LC-MS analysis of 
donepezil hydrochloride after hydrolytic degradation 
under alkali conditions (5 mol/L NaOH) at 80 °C for 1 
h. Several degradation product peaks were noted in 
the HPLC chromatogram as main degradation pro-
ducts of donepezil after degradation under alkali con-
ditions, at relative retention times (RRT) 0.38, 0.41 
and 0.43 (Figure 2b). The compounds were detected 
at m/z 410.1948, 396.2162 and 412.2109 (corres-
ponding to theirs exact molecular masses of 409.1875, 
395.2089 and 411.2036) with molecular formula 
C24H27NO5, C24H29NO4 and C24H29NO5, respectively. 
The molecular mass, found value of m/z and pro-
posed molecular formula of all potential donepezil hyd-
rochloride degradation products are given in Table 1. 
The results of LC-MS analysis of donepezil 
hydrochloride under oxidative degradation are given 
in Table 2. The oxidative experiment indicated 
degradation. Based on liquid chromatography results 
12% of donepezil degradation was achieved. Main 
degradation product was observed at relative retention 
time 1.79. The compound was detected at m/z 
396.2162 (corresponding to its exact molecular mass 
of 395.2089) with molecular formula C24H29NO4. 
Several more degradation products were found at 
relative retention times 0.30, 0.34, 0.48, 0.58, 0.61, 
0.69, 0.71 and 1.74 (Figure 2c). The compounds were 
detected at m/z 290.1736, 412.2103, 396.2157, 
366.2051, 396.2158, 412.2108, 366.2053 and 
396.2162 (corresponding to theirs exact molecular 
masses of 289.1664, 411.2033, 395.2085, 365.1978, 
395.2085, 411.2035, 365.1980 and 395.2089) with 
molecular formula C17H23NO3, C24H29NO5, C24H29NO4, 
C23H27NO3, C24H29NO4, C24H29NO5, C23H27NO3 and 
C24H29NO4, respectively.  
The results of LC-MS analysis of donepezil 
hydrochloride under thermal degradation (at 105 °C 
for 72 h) are summarized in Table 3. The degradation 
was negligible under thermal treatment with just seve-
ral degradation products but as minute peaks. About 
1% of drug was degraded after exposure of donepezil 
hydrochloride to thermal conditions. Degradation pro-
ducts were found at relative retention times 0.51, 0.58 
and 0.71 (Figure 2d). The compounds were detected 
at m/z 396.2161, 396.2160 and 366.2053 (corres-
ponding to theirs exact molecular mass of 395.2088, 
395.2087 and 365.1980) with molecular formula 
C24H29NO4, C24H29NO4 and C23H27NO3, respectively. 
Forced degradation of donepezil hydrochloride 
under oxidative conditions showed the presence of 
compound at relative retention time 1.79 with mole-
cular formula C24H29NO4, corresponding to donepezil 
Table 1. Results of LC-MS analysis of donepezil hydrochloride in alkali degradation (5 mol/L NaOH) at 80 °C for 1 h. Proposed 
molecular formula for degradation products was determined based on high precision measured masses; λmax values from obtained UV 
spectral data for compounds 
No. RRT λmax / nm Experimental m/z values of important ions Molecular mass and molecular formula 
1 0.20 206; 258; 290 234.1465; 256.1282 233.1392; C14H19NO2 
2 0.30 208; 230; 272; 316 290.1736; 312.1558; 328.1311 289.1664; C17H23NO3 
3 0.34 208; 226sh; 256; 294 412.2103; 434.1920; 450.1648; 845.3975; 861.3715 411.2033; C24H29NO5 
4 0.38 218; 258; 300 410.1948; 432.1795; 448.1525 409.1875; C24H27NO5 
5 0.41 208; 232; 276; 320 396.2162; 418.1980; 434.1728 395.2089; C24H29NO4 
6 0.43 208; 234; 276; 322 412.2109; 434.1940 411.2036; C24H29NO5 
7 0.58 208; 232; 272; 318 366.2051 365.1978; C23H27NO6 
8 0.61 210sh; 228; 272; 316 396.2158; 418.1981; 434.1770 395.2085; C24H29NO4 
9 0.71 208; 232; 276; 320 366.2053 365.1980; C23H27NO3 
10 1.00 208; 230; 270; 316 380.2216; 402.2026; 418.1777 379.2143; C24H29NO3 − donepezil
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Table 2. Results of LC-MS analysis of donepezil hydrochloride in oxidative degradation (3% H2O2) at 80 °C for 1 h. Proposed molecular 
formula for degradation products was determined based on high precision measured masses; λmax values from obtained UV spectral 
data for compounds; sh – shoulder 
No. RRT λmax / nm Experimental m/z values of important ions Molecular mass and molecular formula 
1 0.19 206; 226sh; 260; 290 306.1676; 328.1496; 344.1254; 633.3133 305.1604; C17H23NO4 
2 0.19 206; 260 318.1682 317.1609; C18H23NO4 
3 0.19 206; 260 320.1834 319.1761; C18H25NO4 
4 0.20 206; 258; 290 234.1465; 256.1282 233.1392; C14H19NO2 
5 0.21 210; 248 304.1887 303.1814; C18H25NO3 
6 0.22 208; 262 322.1628; 344.1488; 643.3214; 665.3031; 
681.2760 
321.1558; C17H23NO5 
7 0.22 208; 262 334.1993 333.1921; C19H27NO4 
8 0.22 208; 262 250.1418; 272.1277; 499.2783; 521.2605; 
537.2375 
249.1349; C14H19NO3 
9 0.30 208; 230; 272; 316 290.1736; 312.1558; 328.1311 289.1664; C17H23NO3 
10 0.34 208; 226sh; 256; 294 412.2103; 434.1920; 450.1648; 845.3975; 
861.3715 
411.2033; C24H29NO5 
11 0.38 218; 258; 300 410.1948; 432.1795; 448.1525 409.1875; C24H27NO5 
12 0.42 208; 260; 318 426.1905 425.2187; C24H27NO6 
13 0.43 208; 234; 276; 322 412.2109; 434.1940 411.2036; C24H29NO5 
14 0.48 210sh; 230; 272; 316 396.2157; 418.1979; 434.1747 395.2085; C24H29NO4 
15 0.58 208; 232; 272; 318 366.2051 365.1978; C23H27NO3 
16 0.61 210sh; 228; 272; 316 396.2158; 418.1981; 434.1770 395.2085; C24H29NO4 
17 0.69 208; 234; 274; 310 412.2108; 434.1934; 823.4182 411.2035; C24H29NO5 
18 0.71 208; 232; 276; 320 366.2053 365.1980; C23H27NO3 
19 1.00 208; 230; 270; 316 380.2216; 402.2026; 418.1777 379.2143; C24H29NO3 − donepezil 
20 1.74 208; 230; 270; 316 396.2162; 418.1974; 434.1712 395.2089; C24H29NO4 
21 1.79 208; 230; 270; 316 396.2162; 418.1974; 434.1712 395.2089; C24H29NO4 
Table 3. Results of LC-MS analysis of donepezil hydrochloride in thermal degradation (at 105 °C for 72 h). Proposed molecular formula 
for degradation products was determined based on high precision measured masses; λmax values from obtained UV spectral data for 
compounds; sh – shoulder 
No. RRT λmax / nm Experimental m/z values of important ions Molecular mass and molecular formula 
1 0.20 206; 258; 290 234.1465; 256.1282 233.1392; C14H19NO2 
2 0.26 226; 286; 334 398.2304 397.2231; C24H31NO4 
3 0.30 208; 230; 272; 316 290.1736; 312.1558; 328.1311 289.1664; C17H23NO3 
4 0.34 208; 226sh; 256; 294 412.2103; 434.1920; 450.1648; 845.3975; 
861.3715 
411.2033; C24H29NO5 
5 0.38 258; 318 388.2086; 410.1951 387.2058; C22H29NO5 
6 0.41 208; 232; 276; 320 396.2162; 418.1980; 434.1728 395.2089; C24H29NO4 
7 0.43 208; 234; 276; 322 412.2109; 434.1940 411.2036; C24H29NO5 
8 0.51 208; 232; 274; 310 396.2161; 418.1973 395.2088; C24H29NO4 
9 0.58 208; 232; 272; 312 396.2160; 418.1982 395.2087; C24H29NO4 
10 0.71 208; 232; 276; 320 366.2053 365.1980; C23H27NO3 
11 1.00 208; 230; 270; 316 380.2216; 402.2026; 418.1777 379.2143; C24H29NO3 − donepezil 
 
N-oxide derivate. The degradation of the molecule is 
ascribed to the oxidation of the tertiary amine group to 
amino oxide. The literature has revealed that the 
tertiary amines undergo oxidation to form N-oxide 
while the aromatic nucleus is susceptible to free 
radical catalyzed hydroxylation [25-27]. Also, it is indi-
cative based on the proposed metabolic pathways of 
donepezil that donepezil molecule is susceptible to 
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reactions of O-demethylation at each ethoxy group of 
the dimethoxyindan moiety, N-dealkylation at the 
piperidine ring, N-oxidation at the piperidine ring and 
aromatic hydroxylation [28,29]. 
As we mentioned earlier, no forced degradation 
studies of donepezil hydrochloride using HPLC-MS 
method was reported so far. This integrated approach 
is employed to obtain molecular masses of degrad-
ation products and in order to complete MS analysis, 
LC preparative isolation and NMR spectroscopy mea-
surements of compounds obtained by forced degrad-
ation of donepezil hydrochloride should be carried out 
to fully and accurately characterize their molecular 
structure. This will be the subject of our further inves-
tigation. 
CONCLUSION 
In this work, in-vitro-generated forced degrad-
ation products of donepezil hydrochloride were stu-
died. Donepezil hydrochloride is stable to ICH recom-
mended conditions of hydrolysis, oxidation and dry 
heat. Only a small degradation (∼0.2%) is noted at the 
investigated acid hydrolytic condition and about 1% 
degradation in samples under selected conditions of 
dry heat. On the other hand, significant degradation of 
about 3% degradation under specific alkali hydrolytic 
condition and about 12% degradation in oxidative 
degradation mediated by hydrogen peroxide with 
formation of several degradation products was noted.  
Combined information from retention behavior in 
reversed-phase HPLC and mass spectrometry using 
high resolution mass measurements revealed 
degradation products in forced degradation samples. 
Degradation products were characterized through 
proposed molecular formulas based on precise mass 
measurements obtained through LC-MS analysis. 
Moreover, the peak purity index of donepezil found 
confirmed that donepezil peak is spectrally pure in all 
samples under various degradation conditions and 
based on the above results the method can be used 
for quantitative determination of donepezil hydrochlo-
ride in donepezil hydrochloride tablets in presence of 
his degradation products. The method proved to be 
specific and stability indicating. 
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NAUČNI RAD 
  ANALIZA DEGRADACIONIH PROIZVODA 
DONEPEZILA PRIMENOM TEČNE HROMATO-
GRAFIJE I TEČNE HROMATOGRAFIJE-MASENE 
SPEKTROMETRIJE 
Proučavanje degradacionih proizvoda donepezila je izvršeno korišćenjem RP-HPLC 
metode za određivanje stabilnosti donepezila, leka koji pripada grupi reverzibilnih inhibitora 
acetilholinesteraze. U cilju ispitivanja stabilnosti leka i njegovih degradacionih proizvoda 
sprovedena je studija forsirane degradacije čiste supstance kao i farmaceutskog proizvoda 
pod različitim uslovima. Donepezil-hidrohlorid i donepezil tablete su podvrgnuti različitim 
uslovima degradacije prema preporukama Internacionalne konferencije za harmonizaciju. 
Rastvori donepezil-hidrohlorida su podvrgnuti kiseloj i baznoj hidrolizi, hemijskoj oksidaciji i 
termalnoj degradaciji. Pri baznoj hidrolizi i hemijskoj oksidaciji uočena je značajna degra-
dacija polaznog molekula. Oksidativnom degradacijom nastaju i proizvodi koji nisu uočeni 
kod ostalih postupaka forsirane degradacije. Nastali proizvodi analizirani su novorazvi-
jenom HPLC metodom. Osnovna metoda je modifikovana u cilju dobijanja LC-MS kom-
patibilne metode kako bi se identifikovali nastali degradacioni proizvodi. Na osnovu result-
ata dobijenih masenom spektrometrijom dobijene su tačne mase proizvoda degradacije, 
čime je omogućeno odredivanje njihovih molekulskih formula. 
Ključne reči: donepezil-hidrohlorid, forsirana degradacija, HPLC metoda za 
određivanje stabilnosti, tečna hromatografija-masena spektrometrija. 
 
 
